GF83313761
Platinum
rod, 25mm, diameter 2.0mm, 99.95%
Synonym(s):
Platinum, PT007920
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
MDL number:
UNSPSC Code:
12141734
PubChem Substance ID:
NACRES:
NA.23
Pricing and availability is not currently available.
Recommended Products
Assay
99.95%
form
rod
manufacturer/tradename
Goodfellow 833-137-61
resistivity
10.6 μΩ-cm, 20°C
L × diam.
25 mm × 2.0 mm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
SMILES string
[Pt]
InChI
1S/Pt
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
General description
For updated SDS information please visit www.goodfellow.com.
Legal Information
Product of Goodfellow
Storage Class Code
13 - Non Combustible Solids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Antonio González
Future oncology (London, England), 9(12 Suppl), 29-35 (2013-11-15)
Ovarian carcinoma is still one of the most common causes of death from cancer in the western world. Despite high sensitivity to chemotherapy, the majority of patients will relapse within 3 years. In this article the focus is centered on
Nicoletta Colombo
Future oncology (London, England), 9(12 Suppl), 19-23 (2013-11-15)
Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Himashinie V K Diyabalanage et al.
Cancer letters, 329(1), 1-8 (2012-10-04)
One of the most promising strategies to increase the efficacy of standard chemotherapy drugs is by combining them with low doses of histone deacetylases inhibitors (HDACis). Regarded as chemosensitizers, the addition of well-tolerated doses of HDACis to platinum-based chemotherapeutics has
Pei-Miao Li et al.
Ying yong sheng tai xue bao = The journal of applied ecology, 23(12), 3514-3525 (2013-03-14)
Anthropogenic platinum group elements (PGEs) are widely applied in vehicle exhaust catalytic converters (VECs), industrial catalysts, and pharmaceutics, making the PGEs, especially Pt, Pd, and Rh, become the newly environmental pollutants in some fields. Given the positive correlations between the
Hai-Bo Wei et al.
Chinese medical journal, 125(16), 2902-2907 (2012-08-31)
Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients. To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC, we performed a meta-analysis to compare chemosensitivity to platinum
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
